Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016
The aim of the study was to assess guideline adherence to combined antiretroviral therapy (ART) in the German ClinSurv HIV Cohort and the real-life impact of the Strategic Timing of Antiretroviral Therapy (START) study, to identify patients not treated as recommended by new guidelines.
We used data from the multicenter ClinSurv cohort of the Robert-Koch-Institute (RKI) between 1999 and 2016. Inclusion criteria were people living with HIV/AIDS, ≥ 18 years of age and cART naïve at the first visit (FV). Adherence was defined as starting cART within 6 months of crossing the CD4+ T cell threshold as suggested by the German-Austrian treatment guidelines. Logistic regression was used to identify factors associated with non-adherence.
11,817 patients met the inclusion criteria. We observed an overall adherence rate of 60%, in patients with treatment indication who started cART timely between 2002 and 2015. Adherence rate increased constantly, demonstrating a potential increase in patients, with treatment indication, starting cART within 6 months of presentation from 55% in 2008 to 94% in 2015. Patients reporting injection drug use (OR 2.18, 95% CI 1.70–2.95) and patients between 18 years and 39 years of age at the time of their first visit (OR 2.89, 95% CI 1.35–6.18) were identified as risk groups associated with non-adherence.
The majority of patients below the CD4+ T cell count threshold of applicable guidelines initiated treatment within 6 months. We observed a slowly diminishing proportion of patients not starting cART timely. Delayed treatment was more frequent in patients reporting injection drug use.
KeywordsHIV Antiretroviral therapy START Treatment guidelines Adherence
This study was funded by the German Center for Infection Research. Initial results of this study were presented at the ‘21st International Workshop on HIV and Hepatitis Observational Databases’ in Lisbon, Portugal 2016, Abstract no: 109.
JV and MS designed the study, analyzed and interpreted the data. MS drafted the primary draft of the manuscript. BG, CK and DS provided data, and contributed critically important ideas on how to interpret the data. PS, BG, CK, DS, MP, CL and GF revised the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.
Compliance with ethical standards
Conflict of interest
This study is a project within the TP-HIV by the German Centre for Infection Research (DZIF) (NCT02149004). We declare that all authors have no conflicts of interest.
- 5.May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. Br Med J. 2011;343:11.Google Scholar
- 6.UNAIDS. Fact sheet—latest statistics on the status of the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed Feb 2018.
- 7.UNAIDS. 90-90-90—an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations; 2014.Google Scholar
- 10.Grinsztejn B, Hosseinipour MC, Ribaudo HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14:281–90.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Panel on Antiretroviral Guidelines for Adults and Adolescents. US-Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf. Accessed January 2018.
- 19.Waters L, Ahmed N, Angus B, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf. Accessed Oct 2017.
- 20.EACS. European Guidelines for treatment of HIV-positive adults in Europe 8.0. http://www.eacsociety.org/files/guidelines_8.0-english-revised_20160610.pdf. Accessed Oct 017.
- 21.Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch -Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. http://www.daignet.de/site-content/hiv-therapie/leitlinien-1. Accessed Oct 2017.
- 22.Deutsche AIDSG. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2014.Google Scholar
- 23.Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2012.Google Scholar
- 24.Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch -Österreichische Leitlinien zur Therapie der HIV-Infektion 2010, 2010.Google Scholar
- 27.Deutsche AIDS-Gesellschaft. Österreichische AIDS-Gesellschaft. Deutsch -Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2002. Dtsch Med Wochenschr 2003; (128): S7-S18.Google Scholar
- 28.Deutsche AIDS-Gesellschaft, Österreichische. AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2008. 2008.Google Scholar
- 30.Centers for Disease Control and Prevention. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recommend Rep Morbid Mortal Week Rep Recommend Rep 1992. 1993;41:1–19.Google Scholar
- 32.INSIGHT START Study Group. Strategic timing of antiretroviral treatment (START) study primary results. In: 8th IAS conference on HIV pathogenesis treatment and prevention. Vancouver, Canada, 2015.Google Scholar
- 33.Danel C, Moh R, Gabillard D, et al. Early ART and IPT in HIV-infected African adults with high CD4 Count (Temprano Trial). Conference on retroviruses and opportunistic infections. Seattle, WA, USA, 2015.Google Scholar
- 34.Stecher M, Chaillon A, Eis-Hubinger AM, et al. Pre treatment HIV-1 drug resistance in transmission clusters of the Cologne-Bonn Region, Germany. Clin Microbiol Infect 2018.Google Scholar
- 38.Rebolledo P, Kourbatova E, Rothenberg R, del Rio C. Factors associated with utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, Georgia. J AIDS HIV Res (Online). 2011;3:63–70.Google Scholar
- 39.Robert-Koch-Institut. Epidemiologisches Bulletin 45, page 476–483. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/45_15.pdf?__blob=publicationFile. Accessed Jun 2017.
- 40.Vourli G, Pharris A, Cazein F, et al. Assessing the representativeness of European HIV cohort participants as compared to HIV surveillance data. In: Control ECfDPa. HepHIV. Malta, 2017.Google Scholar